Organization
Eli Lilly and Company, Indianapolis, United States
6 abstracts
Abstract
A RAPID3-LIKE INDEX DOCUMENTS SUPERIOR EFFICACY OF BARICITINIB TO ADALIMUMAB AND PLACEBO, SIMILAR TO DAS28 AND CDAI IN THE RA-BEAM CLINICAL TRIAL IN PATIENTS WITH RHEUMATOID ARTHRITIS Org: Rush University Medical Center, Chicago, IL, Eli Lilly and Company, Indianapolis, United States,
Abstract
A HIGH LEVEL OF CLINICAL RESPONSE BASED ON COMPOSITE INDICES IS ASSOCIATED WITH IMPROVED HEALTH-RELATED QUALITY OF LIFE: ANALYSES FROM A PHASE 3 CLINICAL TRIAL IN PATIENTS WITH RHEUMATOID ARTHRITIS Org: Eli Lilly and Company, Indianapolis, United States,
Abstract
ANALYSIS OF NEUTROPHILS, LYMPHOCYTES, AND PLATELETS IN POOLED PHASE 2 AND PHASE 3 STUDIES OF BARICITINIB FOR RHEUMATOID ARTHRITIS Org: Albany Medical College, New York, United States, Leiden University Medical Center, Leiden, Netherlands, Eli Lilly and Company, Indianapolis, United States,
Abstract
BARICITINIB VERSUS ADALIMUMAB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: ANALYSIS OF PATIENTS ACHIEVING A MODERATE EULAR RESPONSE AT WEEK 4 Org: Eli Lilly and Company, Indianapolis, United States,
Abstract
BARICITINIB, AN ORAL JANUS KINASE INHIBITOR, IN THE TREATMENT OF RHEUMATOID ARTHRITIS: SAFETY AND EFFICACY IN OPEN-LABEL, LONG-TERM EXTENSION STUDY Org: Eli Lilly and Company, Indianapolis, United States, Mt Sinai, Ontario, Canada,
Abstract
BARICITINIB, AN ORAL JANUS KINASE (JAK)1/JAK2 INHIBITOR, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA) AND AN INADEQUATE RESPONSE TO CDMARD THERAPY: RESULTS OF THE PHASE 3 RA-BUILD STUDY Org: Department of Rheumatology, Cochin Hospital, Paris, France, Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, Chang Gung Memorial Hospital, Kaohsiung, Taiwan, Province of China, Desert Medical Advances, Palm Desert, United States, Veszprém Csolnoky Ferenc County Hospital, Vészprem, Hungary,